Lilly Asia Ventures, a healthcare-focused venture capital firm backed by global pharmaceutical giant Eli Lilly & Co., has received a commitment of US$40 million for its fifth biosciences fund, LAV Biosciences Fund V, from U.S. public pension San Francisco City & County Employees’ Retirement System (SFERS). This is part of the pension fund’s latest alternative […] Lilly Asia Ventures Receives $40M Commitment From US Pension Fund SFERS comes originally from China Money Network. All Rights Reserved.